个人简介：

现任中山大学医学院教授，博士生导师，院长助理。担任“广东省药监局血液肿瘤靶向药物药效与安全评价重点实验室”主任，“深圳市炎症性疾病系统医学重点实验室”副主任。2011年于苏州大学药学院取得博士学位，2012年前往美国MD安德森肿瘤中心进行博士后研究，2016年获聘美国西北大学助理教授，2017年获聘中山大学“百人计划”引进人才。2021年获深圳市高层次专业人才认定，2022年获中山大学“逸仙学者”新锐学者称号。已在肿瘤学以及药理学方向发表高水平学术论文26篇，其中以第一作者及通讯作者在Cancer Cell, Autophagy, Oncogene等杂志上发表论文15篇，总引用率大于1000次，独立他引次数超过500次。ISI Web of Knowledge引用数据统计表明，其中4篇论文分别进入年度生物医学世界前 1-10%高引用率论文，另外2篇论文分别进入年度生物医学世界前10%-20%高引用率论文。迄今为止主持国家自然科学基金3项和其他项目6项。

研究方向

多发性骨髓瘤；泌尿系统肿瘤；紧密连接蛋白；化疗耐药；血管生成；原位人源小鼠肿瘤移植模型。

学科专业：

肿瘤药理学

重要学术研究成果与贡献：

(1)创新性的提出紧密连接蛋白TJP1作为骨髓瘤化疗耐药的生物标记物，为骨髓瘤和相关血液肿瘤的精准诊断和治疗提供了有效的理论基础。
(2)深入探索TJP1上下游调控机制，阐明TJP1调节血管生成在膀胱癌中的发病机制，为临床治疗提供新思路。
(3)发现密封蛋白OCLN对IL8-STAT信号通路介导血管生成并调节了膀胱癌的转移。

实验室主要研究方向：

围绕肿瘤转移相关的紧密连接蛋白家族分子，探究其在肿瘤化疗耐药、精准诊断和转化应用中的作用。

学科专业：药理学

招生学科专业：学术博士/硕士100706 药理学； 专业博士/硕士 086000 生物与医药。

联系方式：zhangxd39@mail.sysu.edu.cn

本实验室长期招聘具有基础医学和生物学背景的专职科研人员，博士后，招收硕、博士生，诚挚欢迎有志于肿瘤生物学研究的同仁加入！

部分著作

1.    Chan S, Liu Z, Chen Y, Chen S, Liang Y, Yang Z, Zhang Z, Li M, Zhang X*, Liu X*. The JAK-STAT signaling-related signature serves as a prognostic and predictive biomarker for renal cell carcinoma immunotherapy. Gene. 2024 Jun 23:148719. doi: 10.1016/j.gene.2024.148719. Online ahead of print.
2.    Li M, Zhang CL, Zhou DS, Chan SH, Liu XQ, Chen SN, Yang ZY, Ju FE, Sang XY, Liu ZX, Zhang QX, Pan YM, Deng SS, Wang XM, Zhong L, Zhang XD*, Du X*. Identification of COQ2 as a regulator of proliferation and lipid peroxidation through genome-scale CRISPR-Cas9 screening in myeloma cells. Br J Haematol. 2024 Mar 10. doi: 10.1111/bjh.19375.
3.    Huang Y, Chan S, Chen S, Liu X, Li M, Zheng L, Dong Z, Yang Z, Liu Z, Zhou D, Zhang X*, Zhang B*. Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer. J Transl Med. 2024 Feb 3;22(1):133.
4.    Li M, Zhou DS, Shao XR, Chan SH, Dong ZX, Liu XQ, Chen SN, Qi L, Zarate LV, Wang XM, Du X, Zhang XD*. Tight Junction Protein 1 Suppresses Kidney Renal Clear Cell Carcinoma Cells Proliferation by Inducing Autophagy. Int J Med Sci. 2023 Sep 11;20(11):1448-1459.
5.    Chen SN, Mai ZY, Mai JN, Liang W, Dong ZX, Ju FE, Chan SH, Fang Z, Xu Y, Uziel O, He C, Zhang XD*, Zheng Y*. E2F2 modulates cell adhesion through the transcriptional regulation of PECAM1 in multiple myeloma. Br J Haematol. 2023 Aug;202(4):840-855.
6.    Dong ZX, Chan SH, Chen SN, Li M, Zhang XD*, Liu XQ*. TJP1 promotes vascular mimicry in bladder cancer by facilitating VEGFA expression and transcriptional activity through TWIST1. Transl Oncol. 2023 Jun:32:101666.
7.    Liyuan Zheng, Disheng Zhou, Feier Ju, Zixuan Liu, Chenzhi Yan, Zhaoxiao Dong, Shuna Chen, Lizhi Deng, Sikai Chen, Junjie Deng*, and Xingding Zhang*. Oscillating Fluid Flow Activated Osteocyte Lysate-based Hydrogel for Regulating Osteoblast/Osteoclast Homeostasis to Enhance Bone Repair. Advanced Science. 2023. 10.1002/advs.202204592.
8.    Fan Yang#, Xue-Qi Liu#, Jian-Zhong He, Shi-Ping Xian, Peng-Fei Yang, Zhi-Ying Mai, Miao Li*, Ye Liu*, Xing-Ding Zhang*. Occludin facilitates tumour angiogenesis in bladder cancer by regulating IL8/STAT3 through STAT4. J Cell Mol Med. 2022;26(8):2363-2376. 
9.    Yuanyuan Shi, Jian Chen, Wei-Jie Zeng, Miao Li, Wenxue Zhao, Xing-Ding Zhang* and Jie Yao*. Formation of nuclear condensates by the Mediator complex subunit Med15 in mammalian cells. BMC Biology (2021) 19:245.
10.    Xue-Qi Liu#, Xin-Rong Shao#, Ye Liu#, Zhao-Xia Dong, Sze-Hoi Chan, Yuan-Yuan Shi, Shu-Na Chen, Lin Qi1, Li Zhong, Yue Yu, Ting Lv, Peng-Fei Yang, Li-Yan Li, Xiao-Bin Wang, Xu-Dong Zhang, Xin Li, Wenxue Zhao, Lalit Sehgal, Miao Li* and Xing-Ding Zhang*. Tight junction protein 1 promotes vasculature remodeling via regulating USP2/TWIST1 in bladder cancer. Oncogene. 2021;  41:502–514.
11.    Bo Zhang#, Sze-Hoi Chan#, Xue-Qi Liu, Yuan-Yuan Shi, Zhao-Xia Dong, Xin-Rong Shao, Li-Yuan Zheng, Zhi-Ying Mai, Tian-Liang Fang, Li-Zhi Deng, Di-Sheng Zhou, Shu-Na Chen*, Miao Li*, Xing-Ding Zhang*. Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancer. J Cell Mol Med. 2021;25(18):8836-8849.
12.    Chun Liu#*, Miao Li# , Zhao-Xia Dong, Dong Jiang, Xiaojing Li, Shuibin Lin, Demeng Chen, Xuenong Zou, Xing-Ding Zhang* , Gary D Luker*.Heterogeneous microenvironmental stiffness regulates pro-metastatic functions of breast cancer cells. Acta Biomater. 2021;131:326-340.
13.    Miao Li#, Lin Qi#*, Jing-Bo Xu#, Li-Ye Zhong, Szehoi Chan, Shu-Na Chen, Xin-Rong Shao, Li-Yuan Zheng, Zhao-Xia Dong, Tian-Liang Fang, Zhi-Ying Mai, Juan Li, Yongjiang Zheng*, Xing-Ding Zhang*. Methylation of the promoter region of the Tight Junction Protein-1 by DNMT1 induces Epithelial-Mesenchymal Transition-like features in multiple myeloma. Molecular Therapy: Oncolytics. 2020;19:197-207. 
14.    Lin Qi, Zhong-Yong Wang, Xin-Rong Shao, Miao Li, Shu-Na Chen, Xue-Qi Liu, Shi Yan, Bo Zhang, Xu-Dong Zhang, Xin Li, Wenxue Zhao, Ji-An Pan, Bo Zhao, Xing-Ding Zhang*. ISL2 modulates angiogenesis through transcriptional regulation of ANGPT2 to promote cell proliferation and malignant transformation in oligodendroglioma. Oncogene. 2020. 39(37):5964-5978. PMID: 32753650. 
15.    Xing-Ding Zhang, Veerabhadran Baladandayuthapani, Heather Lin, George Mulligan, Bin Li, Dixie-Lee W. Esseltine, Lin Qi, Jianliang Xu, Walter Hunziker, Bart Barlogie, Saad Z. Usmani, Qing Zhang,John Crowley, Antje Hoering, Jatin J. Shah, Donna M. Weber, Elisabet E. Manasanch, Sheeba K. Thomas, Bing-Zong Li, Hui-Han Wang, Jiexin Zhang, Isere Kuiatse, Jin-Le Tang, Hua Wang, Jin He, Jing Yang,Enrico Milan, Simone Cenci, Wen-Cai Ma, Zhi-Qiang Wang, Richard Eric Davis, Lin Yang* and Robert Z. Orlowski*. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. 2016; 9;29(5):639-52. 

专利：
1. 一种骨细胞裂解液基/囊泡基水凝胶及其制备方法和应用。张幸鼎；郑莉媛；周迪生；郑永江。授权日：2023年8月8日。授权号：ZL202210903462.9
2.膀胱癌生物标志物TJP1及其应用。张幸鼎；刘雪琦；李淼；邵欣荣；齐琳；潘纪安。授权日：2019年12月16日。授权号：ZL201911292206.5